Seminars in Nuclear Medicine
Volume 39, Issue 4 , Pages 276-289 , July 2009

Hybrid Imaging by SPECT/CT and PET/CT: Proven Outcomes in Cancer Imaging

  • Andreas Bockisch, MD

      Affiliations

    • Department of Nuclear Medicine, University Hospital of Essen, Essen, Germany
    • Corresponding Author InformationAddress reprint requests to Andreas Bockisch, MD, Department of Nuclear Medicine, University Hospital of Essen, Hufelandstr. 55, 45122 Essen, Germany
    • ,
  • Lutz S. Freudenberg

      Affiliations

    • Department of Nuclear Medicine, University Hospital of Essen, Essen, Germany
    • ,
  • Daniela Schmidt

      Affiliations

    • Clinic of Nuclear Medicine, University of Erlangen-Nürnberg, Erlangen, Germany
    • ,
  • Torsten Kuwert

      Affiliations

    • Clinic of Nuclear Medicine, University of Erlangen-Nürnberg, Erlangen, Germany

References 

  1. Townsend DW, Beyer T. A combined PET/CT scanner: The path to true image fusion. Br J Radiol. 2002;75 Spec No:S24–S30
  2. Warburg O, Wind F, Neglers E. On the Metabolism of Tumors in the Body. In: London: Constable; 1930;p. 254–270
  3. Engel H, Steinert H, Buck A, et al. Whole-body PET: Physiologic and artifactual fluoro-deoxyglucose accumulations. J Nucl Med. 1996;37:441–446
  4. Lindholm P, Minn H, Leskinen-Kallio S, et al. Influence of the blood glucose concentration on FDG uptake in cancer—A PET study. J Nucl Med. 1993;34:1–6
  5. Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42(Suppl 5):1–93
  6. Knapp WH. Leitlinie zur Tumordarstellung mit (F-18)-Fluordeoxyglukose (FDG). Nuklearmedizin. 1999;38:267–269
  7. Reske SN, Kotzerke J. FDG-PET for clinical use (Results of the 3rd German Interdisciplinary Consensus Conference, “Onko-PET III”, 21 July and 19 September 2000). Eur J Nucl Med. 2001;28:1707–1723
  8. Diederichs CG, Staib L, Vogel J, et al. Values and limitations of 18F-fluorodeoxyglucosepositronemission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas. 2000;20:109–116
  9. Weber WA, Avril N, Schwaiger M. Relevance of positron emission tomography (PET) in oncology. Strahlenther Onkol. 1999;175:356–373
  10. Adams S, Baum RP, Stuckensen T, et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med. 1998;25:1255–1260
  11. Buell U, Wieres FJ, Schneider W, et al. 18FDGPET in 733 consecutive patients with or without side-by-side CT evaluation: Analysis of 921 lesions. Nuklearmedizin. 2004;43:210–216
  12. Reinartz P, Wieres FJ, Schneider W, et al. Side-by-side reading of PET and CT scans in oncology: Which patients might profit from integrated PET/CT?. Eur J Nucl Med Mol Imaging. 2004;31:1456–1461
  13. Hutton BF, Braun M. Software for image registration: Algorithms, accuracy, efficacy. Semin Nucl Med. 2003;33:180–192
  14. Beyer T, Rosenbaum S, Veit P, et al. Respiration artifacts in whole-body (18)F-FDG PET/CT studies with combined PET/CT tomographs employing spiral CT technology with 1-16 detector rows. Eur J Nucl Med Mol Imaging. 2005;32:1429–1439
  15. Beyer T, Townsend DW, Blodgett TM. Dualmodality PET/CT tomography for clinical oncology. Q J Nucl Med. 2002;46:24–34
  16. Antoch G, Freudenberg LS, Beyer T, et al. To enhance or not to enhance? (18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT). J Nucl Med. 2004;45(Suppl 1):56S–65S
  17. Antoch G, Freudenberg LS, Egelhof T, et al. Focal tracer uptake: A potential artifact in contrast enhanced dual-modality PET/CT scans. J Nucl Med. 2002;43:1339–1342
  18. Antoch G, Stattaus J, Nemat AT, et al. Non–small-cell lung cancer: Dual-modality PET/CT in preoperative staging. Radiology. 2003;229:526–533
  19. Beyer T, Antoch G, Muller S, et al. Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med. 2004;45(Suppl 1):25S–35S
  20. Goerres GW, Kamel E, Heidelberg TN, et al. PET/CT image coregistration in the thorax: Influence of respiration. Eur J Nucl Med Mol Imaging. 2002;29:351–360
  21. Goerres GW, Burger C, Schwitter MR, et al. PET/CT of the abdomen: Optimizing the patient breathing pattern. Eur Radiol. 2003;13:734–739
  22. Beyer T, Antoch G, Blodgett T, et al. Dual-modality PET/CT imaging: The effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging. 2003;30:588–596
  23. Cohade C, Osman M, Marshall LN, et al. PETCT: Accuracy of PET and CT spatial registration of lung lesions. Eur J Nucl Med Mol Imaging. 2003;30:721–726
  24. Beyer T, Antoch G, Bockisch A, et al. Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT. J Nucl Med. 2005;46:429–435
  25. Heusner TA, Fronz U, Jentzen W, et al. The effect of different chemoembolization materials on CT-based attenuation correction in PET/CT. Rofo. 2007;179:1159–1165
  26. Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: Literature-based evidence as of September 2006. J Nucl Med. 2007;48:78S–88S
  27. Halpern BS, Schiepers C, Weber WA, et al. Presurgical staging of non–small-cell lung cancer: PET and PET/CT in NSCLC positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest. 2005;128:2289–2297
  28. Kim JH, Czernin J, Allen-Auerbach MS, et al. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med. 2005;46:587–595
  29. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon (Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer). N Engl J Med. 1985;312:1604–1608
  30. Freudenberg LS, Pink R, Beyer T, et al. FDG-PET/CT bei Bronchialkarzinomen. Der. Nuklearmediziner. 2003;9:273–277
  31. Chee KG, Nguyen DV, Brown M, et al. Positron emission tomography and improved survival in patients with lung cancer: The Will Rogers phenomenon revisited. Arch Intern Med. 2008;28:1541–1549
  32. Freudenberg LS, Antoch G, Jentzen W, et al. Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol. 2004;14:2092–2098
  33. Freudenberg LS, Antoch G, Frilling A, et al. Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: Role of 124I-PET/CT and FDG-PET. Eur J Nucl Med Mol Imaging. 2008;35:950–977
  34. Freudenberg LS, Jentzen W, Görges R, et al. 124I-PET dosimetry in advanced differentiated thyroid cancer: Therapeutic impact. Nuklearmedizin. 2007;46:121–128
  35. Jentzen W, Freudenberg L, Eising EG, et al. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med. 2008;49:1017–1023
  36. Jentzen W, Weise R, Kupferschläger J, et al. Iodine-124 PET dosimetry in differentiated thyroid cancer: Recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging. 2008;35:611–623
  37. Buchmann I, Henze M, Engelbrecht S, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617–1626
  38. Buck AK, Stollfuss JC, Stahl A, et al. Nuclear medical diagnostics for liver tumors. Internist. 2007;48:21–24
  39. Bouchelouche K, Oehr P. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: An update review. J Urol. 2008;179:34–45
  40. Larson SM, Schöder H. Advances in positron emission tomography applications for urologic cancers. Curr Opin Urol. 2008;18:65–70
  41. Kotzerke J, Volkmer BG, Glatting G, et al. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin. 2003;42:25–30
  42. Husarik DB, Miralbell R, Dubs M, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:253–263
  43. Rinnab L, Mottaghy FM, Blumstein NM, et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int. 2007;100:786–793
  44. Seo Y, Mari C, Hasegawa BH. Technological development and advances in single-photon emission computed tomography/computed tomography. Semin Nucl Med. 2008;38:77–198
  45. O'Connor MK, Kemp BJ. Single-photon emission computed tomography/computed tomography: Basic instrumentation and innovations. Semin Nucl Med. 2006;36:258–266
  46. Keidar Z, Israel O, Krausz Y. SPECT/CT in tumor imaging: Technical aspects and clinical applications. Semin Nucl Med. 2003;33:205–218
  47. Schillaci O. Hybrid SPECT/CT: A new era for SPECT imaging?. Eur J Nucl Med Mol Imaging. 2005;32:521–524
  48. Krausz Y, Israel O. Single-photon emission computed tomography/computed tomography in endocrinology. Semin Nucl Med. 2006;36:267–274
  49. Schillaci O. Single-photon emission computed tomography/computed tomography in lung cancer and malignant lymphoma. Semin Nucl Med. 2006;36:275–285
  50. Horger M, Bares R. The role of single-photon emission computed tomography/computed tomography in benign and malignant bone disease. Semin Nucl Med. 2006;36:286–294
  51. Sodie DB, Sodie AE, Bakale G. Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med. 2007;37:17–28
  52. Husarik DB, Steinert HC. Single-photon emission computed tomography/computed tomography for sentinel node mapping in breast cancer. Semin Nucl Med. 2007;37:29–33
  53. Schillaci O, Filippi L, Manni C, et al. Single-photon emission computed tomography/computed tomography in brain tumors. Semin Nucl Med. 2007;37:34–47
  54. Mariani G, Flotats A, Israel O. Clinical Applications of SPECT/CT: New Hybrid Nuclear Medicine Imaging System. Vienna: International Atomic Energy Agency; 2008;
  55. Buck AK, Nekolla S, Ziegler S, et al. SPECT/CT. J Nucl Med. 2008;49:1305–1309
  56. Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med. 2005;46:1356–1367
  57. Love C, Din AS, Tomas MB, et al. Radionuclide bone imaging: An illustrative review. Radiographics. 2003;23:341–358
  58. Van den Bosch MA, Hollingworth W, Kimmonth AL, et al. Evidence against the use of lumbar spine radiography for low back pain. Clin Radiol. 2004;59:69–76
  59. Horger M, Eschmann SM, Pfannenberg C, et al. Evaluation of combined transmission and emission tomography for classification of skeletal lesions. AJR. 2004;183:655–661
  60. Römer W, Nömayr A, Uder M, et al. SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients. J Nucl Med. 2006;47:1102–1106
  61. Utsunomiya D, Shiraishi S, Imuta M, et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: Comparison with scintigraphy alone and nonfused scintigraphy and CT. Radiology. 2006;238:264–271
  62. Strobel K, Burger C, Seifert B, et al. Characterization of focal bone lesions in the axial skeleton: Performance of planar bone scintigraphy compared with SPECT and SPECT fused with CT. AJR. 2007;188:W467–W474
  63. McDougall IR. Thyroid Cancer in Clinical Practice. London: Springer; 2007;
  64. Schlumberger M, Pacini F. Thyroid Tumors. In: (ed 5). Paris: Éditions Nucléon; 2003;p. 3–317
  65. Gimm O, Brauckhoff M, Thanh PN, et al. An update on thyroid surgery. Eur J Nucl Med Mol Imaging. 2002;29(Suppl 2):S447–S452
  66. Schmidt D, Szikszai A, Linke R, et al. Impact of 131I SPECT/spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation. J Nucl Med. 2009;50:18–23
  67. Shapiro B, Rufini V, Jarwan A, et al. Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body I-131 scans in patients with thyroid cancer. Semin Nucl Med. 2000;30:115–132
  68. Tharp K, Israel O, Hausmann J, et al. Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2004;31:1435–1442
  69. Ruf J, Lehmkuhl L, Bertram H, et al. Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma. Nucl Med Commun. 2004;25:1177–1782
  70. Chen L, Luo Q, Shen Y, et al. Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma. J Nucl Med. 2008;49:1952–1957
  71. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med. 2002;32:84–91
  72. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228–247
  73. Perri M, Erba P, Volterrani D, et al. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. Q J Nucl Med Mol Imaging. 2008;52:323–333
  74. Krausz Y, Keidar Z, Kogan I, et al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumors. Clin Endocrinol. 2003;59:565–573
  75. Pfannenberg AC, Eschmann SM, Horger M, et al. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2003;30:835–843
  76. Hillel PG, van Beek EJ, Taylor C, et al. The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumors. Clin Radiol. 2006;61:579–587
  77. Reubi JC, Maecke HR. Peptide-based probes for cancer imaging. J Nucl Med. 2008;49:1735–1738
  78. Jager PL, Chirakal R, Marriott CJ, et al. 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: Basic aspects and emerging clinical applications. J Nucl Med. 2008;49:573–586
  79. Ilias I, Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab. 2004;89:479–491
  80. Ozer S, Dobrozemsky G, Kienast O, et al. Value of combined XCT/SPECT technology for avoiding false positive planar 123I-MIBG scintigraphy. Nuklearmedizin. 2004;43:164–170
  81. Franzius C, Hermann K, Weckesser M, et al. Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic nervous system: Feasibility study and comparison with 123I-MIBG SPECT/CT. J Nucl Med. 2006;47:1635–1642
  82. Rozovsky K, Koplewitz BZ, Krausz Y, et al. Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. Am J Roentgenol. 2008;190:1085–1090
  83. Even-Sapir E, Keidar Z, Sachs J, et al. The new technology of combined transmission and emission tomography in evaluating endocrine neoplasms. J Nucl Med. 2001;42:998–1004
  84. Chajari M, Lacroix J, Peny AM, et al. Gallium-67 scintigraphy in lymphoma: Is there a benefit of image fusion with computed tomography?. Eur J Nucl Med Mol Imaging. 2002;29:380–387
  85. Palumbo B, Sivolella S, Palumbo I, et al. 67Ga-SPECT/CT with a hybrid system in the clinical management of lymphoma. Eur J Nucl Med Mol Imaging. 2005;32:1011–1017
  86. Carrera D, Bajen MT, Mora J, et al. Clinical utility of fused 67Ga SPECT/CT scan images in patients with lymphoma. Rev Esp Med Nucl. 2006;25:3–9
  87. Filippi L, Schillaci O, Santoni R, et al. Usefulness of SPECT/CT with a hybrid camera for the functional anatomical mapping of primary brain tumors by [Tc 99m] tetrofosmin. Cancer Biother Radiopharm. 2006;21:41–48
  88. Wong TZ, Turkington TG, Polascik TJ, et al. ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology. AJR Am J Roentgenol. 2005;184:676–680
  89. Schillaci O, Danieli R, Filippi L, et al. Scintimammography with a hybrid SPECT/CT imaging system. Anticancer Res. 2007;27:557–562
  90. Sergiacomi G, Schillaci O, Leporace M, et al. Integrated multislice CT and Tc99m sestamibi SPECT-CT evaluation of solitary pulmonary nodules. Radiol Med. 2006;111:213–224
  91. Luciani A, Itti E, Rahmouni A, et al. Lymph node imaging: Basic principles. Eur J Radiol. 2006;58:338–344
  92. Mariani G, Moresco L, Viale G, et al. Radioguided sentinel lymph node biopsy in breast cancer surgery. J Nucl Med. 2001;42:1198–1215
  93. Mariani G, Gipponi M, Moresco L, et al. Radioguided sentinel lymph node biopsy in malignant cutaneous melanoma. J Nucl Med. 2002;43:811–827
  94. Even-Sapir E, Lerman H, Lievshitz G, et al. Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system. J Nucl Med. 2003;44:1413–1420
  95. Kretschmer L. Dynamic lymphoscintigraphy and image fusion of SPECT and pelvic CT-scans allow mapping of aberrant pelvic sentinel lymph nodes in malignant melanoma. Eur J Cancer. 2003;39:175–183
  96. Lopez R, Payoux P, Gantet P, et al. Multimodal image registration for localization of sentinel nodes in head and neck squamous cell carcinoma. J Oral Maxillofac Surg. 2004;62:1497–1504
  97. Terada A, Hasegawa Y, Goto M, et al. Sentinel lymph node radiolocalization in clinically negative neck oral cancer. Head Neck. 2006;28:114–120
  98. Lerman H, Metser U, Lievshitz G, et al. Lymphoscintigraphic sentinel node identification in patients with breast cancer: The role of SPECT-CT. Eur J Nucl Med Mol Imaging. 2006;33:329–337
  99. Sherif A, Garske U, de la Torre M, et al. Hybrid SPECT-CT: An additional technique for sentinel node detection of patients with invasive bladder cancer. Eur Urol. 2006;50:83–91
  100. Bilde A, von Buchwald C, Mortensen J, et al. The role of SPECT-CT in the lymphoscintigraphic identification of sentinel nodes in patients with oral cancer. Acta Otolaryngol. 2006;126:1096–1103
  101. Keski-Säntti H, Mätzke S, Kauppinen T, et al. Sentinel lymph node mapping using SPECT-CT fusion imaging in patients with oral cavity squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2006;263:1008–1012
  102. Ishihara T, Kaguchi A, Matsushita S, et al. Management of sentinel lymph nodes in malignant skin tumors using dynamic lymphoscintigraphy and the single-photon-emission computed tomography/computed tomography combined system. Int J Clin Oncol. 2006;11:214–220
  103. Khafif A, Schneebaum S, Fliss DM, et al. Lymphoscintigraphy for sentinel node mapping using a hybrid single photon emission CT (SPECT)/CT system in oral cavity squamous cell carcinoma. Head Neck. 2006;28:874–879
  104. Maza S, Taupitz M, Taymoorian K, et al. Multimodal fusion imaging ensemble for targeted sentinel lymph node management: Initial results of an innovative promising approach for anatomically difficult lymphatic drainage in different tumour entities. Eur J Nucl Med Mol Imaging. 2007;34:378–383
  105. Gallowitsch HJ, Kraschl P, Igerc I, et al. Sentinel node SPECT-CT in breast cancer (Can we expect any additional and clinically relevant information?). Nuklearmedizin. 2007;46:252–256
  106. Nomori H, Ikeda K, Mori T, et al. Sentinel node identification in clinical stage Ia non–small-cell lung cancer by a combined single photon emission computed tomography/computed tomography system. J Thorac Cardiovasc Surg. 2007;134:182–187
  107. Tsujino Y, Kusatake K, Kaneko S, et al. Fusion of single-photon emission computed tomography and computed tomography images of sentinel lymph nodes in extramammary Paget's disease of the scrotum. J Dermatol. 2007;34:712–715
  108. Van der Ploeg IM, Valdes Olmos RA, Nieweg OE, et al. The additional value of SPECT/CT in lymphatic mapping in breast cancer and melanoma. J Nucl Med. 2007;48:1756–1760
  109. Lerman H, Lievshitz G, Zak O, et al. Improved sentinel node identification by SPECT/CT in overweight patients with breast cancer. J Nucl Med. 2007;48:201–206
  110. Beneder C, Fuechsel FG, Krause T, et al. The role of 3D fusion imaging in sentinel lymphadenectomy for vilvar cancer. Gynecol Oncol. 2008;09:76–80
  111. Leijte JA, Valdes Olmos RA, Nieweg OE, et al. Anatomical mapping of lymphatic drainage in penile carcinoma with SPECT-CT: Implications for the extent of inguinal lymph node dissection. Eur Urol. 2008;54:885–890
  112. Ganswindt U, Paulsen F, Corvin S, et al. Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition. BMC Cancer. 2005;5:91
  113. Krengli M, Ballare A, Cannillo B, et al. Potential advantage of studying the lymphatic drainage by sentinel node technique and SPECT-CT image fusion for pelvic irradiation of prostate cancer. Int J Radiat Oncol Biol Phys. 2006;66:1100–1104
  114. Zaidi H, Hasegawa B. Determination of the attenuation map in emission tomography. J Nucl Med. 2003;44:291–315
  115. Fricke E, Fricke H, Weise R, et al. Attenuation correction of myocardial SPECT perfusion images with low-dose CT: Evaluation of the method by comparison with perfusion PET. J Nucl Med. 2005;46:36–744
  116. Schulz V, Nickel I, Nömayr A, et al. Effect of CT-based attenuation correction on uptake ratios in skeletal SPECT. Nuklearmedizin. 2007;46:38–42
  117. Römer W, Fiedler E, Pavel M, et al. Attenuation correction of SPECT images based on separately performed CT: Effect on the measurement of regional uptake values. Nuklearmedizin. 2005;44:20–28
  118. Boucek JA, Turner JH. Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in 131I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2005;32:458–469
  119. Song H, He B, Prideaux A, et al. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med. 2006;47:1985–1994
  120. Schlemmer HP, Pichler BJ, Schmand M, et al. Simultaneous MR/PET imaging of the human brain: Feasibility study. Radiology. 2008;248:1028–1035

PII: S0001-2998(09)00016-6

doi: 10.1053/j.semnuclmed.2009.03.003

Seminars in Nuclear Medicine
Volume 39, Issue 4 , Pages 276-289 , July 2009

Article Tools

* Image Usage & Resolution